Related Experiment Video

Updated: Oct 9, 2026

Analysis of Electrocardiograms and Behavior in Mice from Pregnancy to Lactation Period
06:40

Analysis of Electrocardiograms and Behavior in Mice from Pregnancy to Lactation Period

Published on: April 5, 2024

Beta blockers and lactation: an update

M E Shannon1, S E Malecha, A J Cha

  • 1Searle Pharmaceuticals, Skokie, Illinois, USA.

Journal of Human Lactation : Official Journal of International Lactation Consultant Association
|January 12, 2001
PubMed

Insights

Beta-blockers are frequently used for heart conditions. This review examines the latest data on common beta-blockers, assessing their safety for breastfeeding mothers.

Area of Science:

  • Pharmacology
  • Cardiology
  • Neonatal Medicine

Background:

  • Beta-adrenergic antagonists (beta-blockers) are a cornerstone in managing hypertension, angina pectoris, arrhythmias, and post-myocardial infarction mortality.
  • The widespread use of beta-blockers raises concerns about potential exposure in lactating women and their infants.

Purpose of the Study:

  • To review current data on the safety of commonly prescribed beta-blockers during lactation.
  • To provide healthcare professionals with up-to-date information for managing hypertensive or cardiac conditions in breastfeeding women.

Main Methods:

  • Literature review of recent studies and clinical data.
  • Focus on specific beta-blocker agents: metoprolol, atenolol, propranolol, carvedilol, nadolol, sotalol, and betaxolol.
  • Analysis of pharmacokinetic and pharmacodynamic properties relevant to lactation.

Main Results:

  • Data on the transfer of specific beta-blockers into breast milk varies.
  • Some agents show minimal infant exposure, while others require closer monitoring.
  • Individual patient factors and dosage influence safety profiles.

Conclusions:

  • Most common beta-blockers are generally considered compatible with breastfeeding, but careful consideration is needed.
  • Individualized risk-benefit assessment is crucial for selecting beta-blockers in lactating women.
  • Continued research is essential to refine safety guidelines for beta-blocker use during lactation.

More Related Videos

An Efficient Single-Person Technique for Milk Sampling from Laboratory Mice04:56

An Efficient Single-Person Technique for Milk Sampling from Laboratory Mice

Published on: March 28, 2025

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...